244 related articles for article (PubMed ID: 34085829)
1. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
[TBL] [Abstract][Full Text] [Related]
2. Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome.
Lee KY; Chau CH; Price DK; Figg WD
Cancer Biol Ther; 2022 Dec; 23(1):136-138. PubMed ID: 35129066
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
4. The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.
Kryza T; Bock N; Lovell S; Rockstroh A; Lehman ML; Lesner A; Panchadsaram J; Silva LM; Srinivasan S; Snell CE; Williams ED; Fazli L; Gleave M; Batra J; Nelson C; Tate EW; Harris J; Hooper JD; Clements JA
Mol Oncol; 2020 Jan; 14(1):105-128. PubMed ID: 31630475
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.
Matin F; Jeet V; Srinivasan S; Cristino AS; Panchadsaram J; Clements JA; Batra J;
Clin Chem; 2019 Jun; 65(6):771-780. PubMed ID: 31018918
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
[TBL] [Abstract][Full Text] [Related]
7. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
[TBL] [Abstract][Full Text] [Related]
8. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
[TBL] [Abstract][Full Text] [Related]
9. Kallikreins as biomarkers for prostate cancer.
Hong SK
Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
[TBL] [Abstract][Full Text] [Related]
10. Targeting kallikrein-related peptidases in prostate cancer.
Mavridis K; Avgeris M; Scorilas A
Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
[TBL] [Abstract][Full Text] [Related]
11. Activation and activity of glycosylated KLKs 3, 4 and 11.
Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P
Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661
[TBL] [Abstract][Full Text] [Related]
12. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.
Yoon H; Blaber SI; Debela M; Goettig P; Scarisbrick IA; Blaber M
Biol Chem; 2009 Apr; 390(4):373-7. PubMed ID: 19090718
[TBL] [Abstract][Full Text] [Related]
13. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
14. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
[TBL] [Abstract][Full Text] [Related]
15. Functional roles of human kallikrein-related peptidases.
Sotiropoulou G; Pampalakis G; Diamandis EP
J Biol Chem; 2009 Nov; 284(48):32989-94. PubMed ID: 19819870
[TBL] [Abstract][Full Text] [Related]
16. KLKs and their hormone-like signaling actions: a new life for the PSA-KLK family.
Hollenberg MD
Biol Chem; 2014 Sep; 395(9):915-29. PubMed ID: 25153380
[TBL] [Abstract][Full Text] [Related]
17. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin.
Emami N; Diamandis EP
J Biol Chem; 2008 Feb; 283(6):3031-3041. PubMed ID: 18056261
[TBL] [Abstract][Full Text] [Related]
18. Evolutionary history of tissue kallikreins.
Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
[TBL] [Abstract][Full Text] [Related]
19. KLK-targeted Therapies for Prostate Cancer.
Hannu K; Johanna M; Ulf-Håkan S
EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
[TBL] [Abstract][Full Text] [Related]
20. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]